CRYSVITA (burosumab-twza)
X-LINKED HYPOPHOSPHATEMIC OSTEOMALACIA·+1
ULTRAGENYX PHAR
Indication
FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor
FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor is a rare acquired paraneoplastic metabolic bone disorder caused by excessive neoplastic secretion of fibroblast growth factor 23 (FGF23). Read more about FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor
3 drugs 3 manufacturers
Drugs that treat it
Common FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor therapies.
CRYSVITA (burosumab-twza)
FIBROBLAST GROWTH FACTOR 23 (FGF23) INHIBITORS, MONOCLON AB·X-LINKED HYPOPHOSPHATEMIC OSTEOMALACIA·+1
ULTRAGENYX/KYOW
CRYSVITA (burosumab-twza)
FIBROBLAST GROWTH FACTOR 23 (FGF23) INHIBITORS, MONOCLON AB·X-LINKED HYPOPHOSPHATEMIC OSTEOMALACIA·+1
KYOWA KIRIN, IN
Filter & compare in the drug finder →Opens the drug finder with FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAbout FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor.
FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor is a rare acquired paraneoplastic metabolic bone disorder caused by excessive neoplastic secretion of fibroblast growth factor 23 (FGF23).
Circulating FGF23 binds renal tubular receptors to downregulate sodium-phosphate cotransporters—triggering urinary phosphate wasting and severe hypophosphatemia—while concurrently suppressing renal 1-alpha-hydroxylase to decrease active 1,25-dihydroxyvitamin D synthesis.
This chronic depletion of systemic phosphate impairs bone matrix mineralization in affected skeletal tissue, clinically manifesting as progressive musculoskeletal pain, proximal muscle weakness, gait impairment, osteomalacia, and recurrent insufficiency fractures.
- frontiersin.org
FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor is a rare acquired paraneoplastic metabolic bone disorder caused by excessive neoplastic secretion of fibroblast growth factor 23 (FGF23) Circulating FGF23 binds renal tubular receptors to downregulate sodium-phosphate cotransporters—triggering urinary phosphate wasting and severe hypophosphatemia—while concurrently suppressing renal 1-alpha-hydroxylase to decrease active 1,25-dihydroxyvitamin D sy...
- mdpi.com
FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor is a rare acquired paraneoplastic metabolic bone disorder caused by excessive neoplastic secretion of fibroblast growth factor 23 (FGF23)
- nih.gov
Circulating FGF23 binds renal tubular receptors to downregulate sodium-phosphate cotransporters—triggering urinary phosphate wasting and severe hypophosphatemia—while concurrently suppressing renal 1-alpha-hydroxylase to decrease active 1,25-dihydroxyvitamin D synthesis This chronic depletion of systemic phosphate impairs bone matrix mineralization in affected skeletal tissue, clinically manifesting as progressive musculoskeletal pain, proximal muscle weakness, gait impairment, osteomalacia, and...
Personalize your experience
Follow FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.